Placebo + AMG 301

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chronic Migraine or Episodic Migraine

Conditions

Chronic Migraine or Episodic Migraine

Trial Timeline

Sep 6, 2017 → Feb 4, 2019

About Placebo + AMG 301

Placebo + AMG 301 is a phase 2 stage product being developed by Amgen for Chronic Migraine or Episodic Migraine. The current trial status is completed. This product is registered under clinical trial identifier NCT03238781. Target conditions include Chronic Migraine or Episodic Migraine.

What happened to similar drugs?

20 of 20 similar drugs in Chronic Migraine or Episodic Migraine were approved

Approved (20) Terminated (3) Active (0)
Pegasys® + Pegasys®Chugai PharmaceuticalApproved
alefaceptAstellas PharmaApproved
AlefaceptAstellas PharmaApproved
lysozyme 90 mg + PlaceboEisaiApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03238781Phase 2Completed

Competing Products

20 competing products in Chronic Migraine or Episodic Migraine

See all competitors
ProductCompanyStageHype Score
Levofloxacin 500Dr. Reddy's LaboratoriesPre-clinical
23
mRNA-0184ModernaPhase 1
0
Lubiprostone + Lubiprostone + PlaceboDr. Reddy's LaboratoriesPhase 3
37
macitentan 10 mgBML, Inc.Phase 3
32
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
29
TERN-701Terns PharmaceuticalsPhase 1/2
36
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
23
LY3556050 + PlaceboEli LillyPhase 2
35
THB001Third Harmonic BioPhase 1
11
BriquilimabJasper TherapeuticsPhase 1/2
26
BriquilimabJasper TherapeuticsPhase 1/2
14
BriquilimabJasper TherapeuticsPhase 2
29
Empagliflozin + Matching placeboEli LillyPhase 3
40
LY3461767 + PlaceboEli LillyPhase 1
29
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
44
LY3526318 + PlaceboEli LillyPhase 2
35
PirtobrutinibEli LillyPhase 2
42
Ibrutinib + LY3214996Eli LillyPhase 1
21
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
27
LYR-210Lyra TherapeuticsPhase 2
25